Bandaríkin - enska - NLM (National Library of Medicine)

zydus lifesciences limited - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - carbidopa is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 250 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; pregelatinised maize starch; microcrystalline cellulose; indigo carmine aluminium lake - levodopa/carbidopa gxp is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gxp frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; crospovidone - levodopa/carbidopa genpar is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa genpar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 250 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; pregelatinised maize starch; indigo carmine aluminium lake - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 250 mg - tablet, uncoated - excipient ingredients: crospovidone; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; quinoline yellow aluminium lake; crospovidone; microcrystalline cellulose; pregelatinised maize starch - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Bandaríkin - enska - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets. carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer’s recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions ). carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.